Bionaturis (BNT-MAB), an international reference company developing biological vaccines, has signed a contract with a multinational veterinarian company that will test the efficacy and safety of a vaccine to prevent livestock to be infected by intestinal nematodes -helminthes-. This agreement endorses Bionaturis strategic position as a supplier of vaccines for the veterinarian industry.
These gastrointestinal parasites cause annual losses of 3,000 million Euros in the livestock industry. To combat their effects, companies are using chemical endoparasticides that gradually lose efficacy due to growing phenomena of resistance. For this reason among others, governments and sectorial organizations are recommending a reduction of their use. In preliminary in-vivo tests, Bionaturis vaccine has shown superb protection against the types of helminthes that cause more problems and phenomena of resistance in the field. This product, encoded by the company as BNT004, is a first-in-class preventive treatment, and it could become a real and safe option against the most serious cases of resistance.
Efficacy higher than 65% in mice and lamb trials
BNT004 has already been tested in mice and lamb trials, showing protection values higher than 65%, in all cases, about the reduction of the number of parasites in vaccinated animals versus control. Besides, the vaccine is 100% safe and the treated animals did not show any symptomatology. As outstanding outcome for the livestock industry, challenged and vaccinated animals did not show a loss of weight versus control animals, whereas the challenged un-vaccinated animals did.
BNT004 is protected by a patent application of University of Granada (UGR), active in the main traditional veterinarian markets, out-licensed exclusively to Bionaturis back in 2012. Next trials will be made in the multinational company facilities and they will be finished in the first semester of 2014.
Javier Gallestegui, managing director of Bionaturis, states: “This vaccine complements perfectly the current chemical treatments reducing more and more their use, following the recommendations of international authorities. There are huge possibilities because the growing phenomena of resistance and the corresponding looses for the breeders. Our vaccine would be a first-in-class product in the market for this indication”.
About the UGR research team
Antonio Osuna is professor at UGR and has a vast experience leading research projects. He bosses the research team of Biochemist and Molecular Parasitology at University of Granada.
To point out about their successful career, we find BNT004, another outstanding vaccine to prevent myiasis (produced by Torsalo) -a parasitic disease that causes dramatic damages in the skin of livestock at Center and South America- and a new adjuvant-class that strengthens the efficacy of vaccines, to name a few.